Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Of mice and FVIIIa mimetics: new hemophilia A models for in vivo evaluation. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/bloodadvances.2025018528 · 2026 · Admitted local publication
Development of a novel hemophilia A mouse model to study emicizumab and factor VIII inhibitor risk
10.1182/bloodadvances.2025018691 · 2026 · External reference
Emicizumab state-of-the-art update
10.1111/hae.14524 · 2022 · External reference
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
10.1182/blood-2017-08-801662 · 2017 · External reference
Clinical and treatment characteristics of infants and toddlers less than two years of age with hemophilia: a report from the community counts registry
10.1182/blood-2022-158767 · 2022 · External reference
A hemophilia A mouse model for the in vivo assessment of emicizumab function
10.1182/blood.2019004334 · 2020 · External reference
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
10.1182/blood.2020010331 · 2021 · External reference
Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice
10.3324/haematol.2024.286982 · 2025 · External reference
A novel humanized hemophilia-a mouse model to facilitate preclinical in vivo studies of human specific FVIIIa-mimetic bispecific antibodies
10.1182/blood-2018-99-119012 · 2018 · External reference
Shortened lifespan and lethal hemorrhage in a hemophilia A mouse model
10.1371/journal.pone.0154857 · 2016 · External reference
Additional factor X enhances emicizumab-driven coagulation function in patients with hemophilia A and hemophilia A mice
10.1055/a-2315-8199 · 2025 · External reference
